Lack of antiviral activity of darunavir against SARS-CoV-2

  • Objectives: Given the high need and the absence of specific antivirals for treatment of COVID-19 (the disease caused by severe acute respiratory syndrome-associated coronavirus-2 [SARS-CoV-2]), human immunodeficiency virus (HIV) protease inhibitors are being considered as therapeutic alternatives. Methods: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection. There are currently no definitive data on the safety and efficacy of DRV/cobicistat for the treatment of COVID-19. The in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2 was assessed. Results: DRV showed no antiviral activity against SARS-CoV-2 at clinically relevant concentrations (EC50 > 100 μM). Remdesivir, used as a positive control, demonstrated potent antiviral activity (EC50 = 0.38 μM). Conclusions: Overall, the data do not support the use of DRV for the treatment of COVID-19.

Download full text files

Export metadata

Author:Sandra De MeyerORCiD, Denisa BojkovaORCiDGND, Jindrich CinatlORCiDGND, Ellen van DammeORCiD, Christophe BuyckORCiD, Marnix van LoockORCiD, Brian Woodfall, Sandra CiesekORCiDGND
Pubmed Id:
Parent Title (English):International Journal of Infectious Diseases
Place of publication:Amsterdam [u.a.]
Document Type:Article
Year of Completion:2020
Date of first Publication:2020/05/29
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2020/06/15
Tag:COVID-19; Darunavir; In vitro; SARS-CoV-2
Page Number:4
First Page:7
Last Page:10
© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):License LogoCreative Commons - Namensnennung-Nicht kommerziell - Keine Bearbeitung 4.0